Yale University

Sequana Medical Nv

Novo Nordisk A/s

Dsrco Bv

Jeffrey Testani

Oliver Goedje

Ian Crosbie

Christopher McIntyre

Veena Rao

Gary Desir

Madhav N Devalaraja

Chih-Hung Lo

Rahul Kakkar

A direct sodium removal ('DSR') infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.

Formulations and methods for direct sodium removal in patients having heart failure and/or severe renal dysfunction

The present invention relates to compositions and methods for binding and detecting or measuring renalase. In one embodiment, the renalase binding molecule measures renalase amount or activity. Thus, in diseases and conditions where a measurement of renalase is beneficial, such renalase binding molecules may act as diagnostics.

Methods for measuring Renalase

Formulations and methods for direct sodium removal in patients having severe renal dysfunction

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

Treatment of existing left ventricular heart failure

Growing community of inventors

Guilford, CT, United States of America

Jeffrey Testani